Clinical characteristics of programmed death-1 inhibitors for older patients with advanced pancreatic cancer

Figure 1 Kaplan-Meier curves for progression-free survival and overall survival in patients with pancreatic cancer treated with programmed death-1 inhibitors. A: Correlation between the number of prior systemic therapy lines and progression-free survival (PFS); B: Correlation between high-density lipoprotein levels and PFS; C: Correlation between Eastern Cooperative Oncology Group performance status (ECOG PS) and PFS; D: Correlation between ECOG PS and overall survival (OS); E: Correlation between primary tumor location and PFS; F: Correlation between primary tumor location and OS; G: Correlation between carbohydrate antigen (CA199) levels and PFS; H: Correlation between CA199 levels and OS; I: Correlation between systemic immune-inflammation (SII) index and PFS; J: Correlation between SII index and OS; K: Correlation between neutrophil-to-lymphocyte (NLR) ratio and PFS; L: Correlation between NLR ratio and OS; M: Correlation between prognostic nutritional index (PNI) and PFS; N: Correlation between PNI and OS; O: Correlation between triglyceride (TG) levels and PFS; P: Correlation between TG levels and OS; Q: Correlation between radiotherapy and PFS; R: Correlation between radiotherapy and OS. HDL: High-density lipoprotein; PFS: Progression-free survival; ECOG PS: Eastern Cooperative Oncology Group performance status; OS: Overall survival; CA199: Carbohydrate antigen; SII: Systemic immune-inflammation; NLR: Neutrophil-to-lymphocyte; PNI: Prognostic nutritional index; TG: Triglyceride.